| Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma ME Juweid, S Stroobants, OS Hoekstra, FM Mottaghy, M Dietlein, ... Journal of clinical oncology 25 (5), 571-578, 2007 | 1464 | 2007 |
| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group SF Barrington, NG Mikhaeel, L Kostakoglu, M Meignan, M Hutchings, ... Journal of clinical oncology 32 (27), 3048, 2014 | 1027 | 2014 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 668 | 2011 |
| Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer … D Rischin, RJ Hicks, R Fisher, D Binns, J Corry, S Porceddu, LJ Peters Journal of Clinical Oncology 24 (13), 2098-2104, 2006 | 521 | 2006 |
| Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non–small-cell … MP Mac Manus, RJ Hicks, JP Matthews, A McKenzie, D Rischin, ... Journal of Clinical Oncology 21 (7), 1285-1292, 2003 | 476 | 2003 |
| Evaluation of circulating tumor cells and circulating tumor DNA in non–small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab … EA Punnoose, S Atwal, W Liu, R Raja, BM Fine, BGM Hughes, RJ Hicks, ... Clinical Cancer Research 18 (8), 2391-2401, 2012 | 409 | 2012 |
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ... The Lancet Oncology 19 (6), 825-833, 2018 | 353 | 2018 |
| High rate of detection of unsuspected distant metastases by PET in apparent Stage III non–small-cell lung cancer: implications for radical radiation therapy MP Mac Manus, RJ Hicks, JP Matthews, A Hogg, AF McKenzie, A Wirth, ... International Journal of Radiation Oncology* Biology* Physics 50 (2), 287-293, 2001 | 332 | 2001 |
| MRI-negative PET-positive temporal lobe epilepsy: a distinct surgically remediable syndrome RP Carne, TJ O'brien, CJ Kilpatrick, LR MacGregor, RJ Hicks, MA Murphy, ... Brain 127 (10), 2276-2285, 2004 | 329 | 2004 |
| 90Y-edotreotide for metastatic carcinoid refractory to octreotide DL Bushnell Jr, TM O'Dorisio, MS O'Dorisio, Y Menda, RJ Hicks, ... Journal of Clinical Oncology 28 (10), 1652, 2010 | 323 | 2010 |
| Clinical Impact of 18F Fluorodeoxyglucose Positron Emission Tomography in Patients With Non–Small-Cell Lung Cancer: A Prospective Study V Kalff, RJ Hicks, M P. MacManus, DS Binns, AF McKenzie, RE Ware, ... Journal of clinical oncology 19 (1), 111-118, 2001 | 284 | 2001 |
| 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non–small cell lung cancer RJ Hicks, V Kalff, MP MacManus, RE Ware, A Hogg, AF McKenzie, ... Journal of Nuclear Medicine 42 (11), 1596-1604, 2001 | 283 | 2001 |
| Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer SV Porceddu, E Jarmolowski, RJ Hicks, R Ware, LA Weih, D Rischin, ... Head & Neck: Journal for the Sciences and Specialties of the Head and Neck …, 2005 | 270 | 2005 |
| F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high … MP Mac Manus, RJ Hicks, DL Ball, V Kalff, JP Matthews, E Salminen, ... Cancer 92 (4), 886-895, 2001 | 265 | 2001 |
| Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation MS Hofman, WFE Lau, RJ Hicks Radiographics 35 (2), 500-516, 2015 | 250 | 2015 |
| Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer D Rischin, L Peters, R Hicks, P Hughes, R Fisher, R Hart, M Sexton, ... Journal of Clinical Oncology 19 (2), 535-542, 2001 | 232 | 2001 |
| The utility of 18F-FDG PET for suspected recurrent non–small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification RJ Hicks, V Kalff, MP MacManus, RE Ware, AF McKenzie, JP Matthews, ... Journal of Nuclear Medicine 42 (11), 1605-1613, 2001 | 225 | 2001 |
| Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma A Wirth, JF Seymour, RJ Hicks, R Ware, R Fisher, M Prince, ... The American journal of medicine 112 (4), 262-268, 2002 | 220 | 2002 |
| Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. J vom Dahl, DT Eitzman, ZR Al-Aouar, HL Kanter, RJ Hicks, GM Deeb, ... Circulation 90 (5), 2356-2366, 1994 | 219 | 1994 |
| The clinical impact of 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study V Kalff, RJ Hicks, RE Ware, A Hogg, D Binns, AF McKenzie Journal of Nuclear Medicine 43 (4), 492-499, 2002 | 208 | 2002 |
Professor Michael S. HofmanConsultant Physician, Peter MacCallum Cancer Centre & University of MelbourneVerified email at petermac.org
